SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir's recent report and forward guidance are sparking heated debate, with some celebrating the company's growth in the AI space while others express concerns about its high valuation. The community is divided between those who see long-term potential and those who anticipate a correction. Discussions also involve CEO Karp's commentary and Michael Burry's short position against the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss the potential impact of recent trial results and earnings, with debates focusing on the future of Elevidys and its potential to replace older treatments. The community is weighing positive revenue beats against concerns about trial data and FDA decisions, with some speculating about a potential buyout. Sentiment is mixed, with bulls emphasizing long-term growth potential and bears pointing to regulatory uncertainty and potential market corrections.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid mixed sentiment following earnings, with community discussions focusing on revenue beats versus EPS miss and potential risks related to debt and dilution. While some traders are securing profits, others see the dip as a buying opportunity, especially with ongoing developments in nuclear energy and rare earth elements. The stock's movement is also influenced by broader geopolitical factors affecting the rare earth sector.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amid discussions around Q3 earnings, potential short squeeze, and a possible partnership with Novo Nordisk. Community talking points revolve around the company's growth potential, expansion into new markets like comprehensive testing and international, and revenue acceleration, with some expressing concerns around profitability and volatility. Speculation around partnerships and target prices is also contributing to the heightened interest.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid discussions about its strategic direction and upcoming R2 vehicle launch. The community is focused on the company's potential to compete in the mass market and address existing quality and service concerns. Some are also considering how recent partnerships and fleet orders might impact the company's growth.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab Holdings is trending amid discussions about its earnings potential and recent option activity, with call buying suggesting bullish sentiment. Community members are debating the reasons behind the stock's recent movements, the impact of raised guidance, and whether it represents a long-term growth opportunity in the Southeast Asian market. There is also discussion around a settlement for investors and potential inclusion in the S&P 500.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is experiencing a surge, with community members pointing to its low supply and comparing its potential to ZEC's previous moves. Some traders are noting DASH's undervaluation and increased trading volume, while others speculate about potential integrations and its role in the privacy coin sector. The community also highlights its strong performance amidst a sea of red, attracting day traders.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors discuss a potential offering following recent earnings and a new clinical program, while also considering the impact of a new CFO. The community debates management's spending and strategy, as well as the lawsuit against CMS, with some expressing frustration over the stock's performance despite company progress. Bullish investors focus on revenue growth, potential acquisitions, and positive analyst ratings, while bears cite concerns about dilution and management decisions.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

Goodyear is trending as investors discuss its recent earnings report, with some highlighting better-than-expected results and others expressing concern about the company's financial health. Community members are debating the company's valuation, turnaround potential, and debt reduction efforts. Several are pointing to the stock being potentially undervalued.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to investor reactions to Michael Burry's reported call options and the company's ongoing legal battles with Novo Nordisk over the acquisition of Metsera. Community discussions revolve around the potential outcomes of these lawsuits and their implications for Pfizer's position in the competitive obesity therapeutics market, as well as speculation regarding potential acquisitions like Viking Therapeutics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apollomics shares fell 16% after-hours on Wednesday, even as the company said Nasdaq confirmed it remains in compliance with continued listing requirements, canceling a delisting appeal hearing.&nbsp;Trading in the company’s shares and warrants was halted on Sept. 17 for additional information.Reversal Of Wind-Up PlansThe update came as Apollomics continues to stabilize operations following financial challenges that nearly led to its shutdown. In August, the company announced plans to discontinue all clinical trial activities and wind up its business due to funding shortages.&nbsp;The company later reversed those plans in early September after receiving $4.1 million in PIPE investments and appointing a new management team led by CEO Hung-wen Chen, COO Yi-kuei Chen, and CFO Peter Lin.Focus On Late-Stage Oncology PipelineWith new funding and leadership, Apollomics said it is continuing its global Phase 2 SPARTA clinical trial for its lead drug candidate APL-101, a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations.&nbsp;Apollomics said its lead cancer drug APL-101 has delivered encouraging results in more than 280 patients and remains at the center of its cancer research plans.The company added that its clinical trial partners have all been paid, and work is continuing without interruption. It has also implemented a 12-month plan to maintain its drug pipeline's momentum and ensure&nbsp;the company's financial stability during the next phase of development.Global Expansion PlansApollomics said it plans to leverage its existing China approvals for APL-101 in MET-amplified lung cancer and glioblastoma as a springboard for regulatory filings in Southeast Asia, the Middle East and other emerging markets.The company said it now has 12 employees and expects to have 15 employees by the end of October 2025. The company also expects to shift more roles from China to the U.S. and Taiwan to strengthen operations and ensure that its late-stage cancer drug programs remain on track.Stocktwits Traders Stay Upbeat Despite VolatilityOn Stocktwits, retail sentiment for Apollomics was ‘extremely bullish’ amid a 329% message volume.One user noted that the stock was in a very good position after being halted during the recent market pivot, while another highlighted the ongoing volatility in Apollomics shares.<stembedurl>https://stocktwits.com/Love_To_Learn/message/632496720</stembedurl><stembedurl>https://stocktwits.com/topstockalerts/message/632436028</stembedurl><a href="https://stocktwits.com/symbol/APLM">Apollomics’ stock</a> has doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Apollomics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Apollomics Stock Nosedived 16% After-Hours Today

The stock fell after-hours even after Nasdaq confirmed the biotech had regained compliance with listing standards.

Equity

Why Is Penny Stock Apollomics Trading Higher On Tuesday?

Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC...

Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CalciMedica (CALC Research Report), Apollomics (AP...

Apollomics price target lowered by $12 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript...

Apollomics reports FY23 EPS ($2.32) vs ($8.44) last year

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China...

Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 121.7% in February

Apollomics, Inc. (NASDAQ:APLM  Get Free Report) was the recipient of a large increase in short interest in February. As of February 29th, there was short interest totalling 43,900 shares, an...

Apollomics appoints Plunkett as CFO

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

Apollomics Inc - Ordinary Shares - Class A

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$14.17
Prev Close	$13.97
Open	$15.11
Dividend Yield	0.00%
50-Day Moving Average	$15.63
Beta	0.20
Avg. Volume	72,347.52
PE Ratio	-0.26

52-Week High	$42.12
52-Week Low	$3.66
Market Capitalization	$15.41M
EPS (Annual)	-$52.80
Price to Book	3.17
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

APLM
Apollomics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest APLM News

APLMApollomics Inc - Ordinary Shares - Class A